- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Autonomic neuropathy.
Displaying page 1 of 2.
EudraCT Number: 2008-002855-26 | Sponsor Protocol Number: Droxidopa-301 | Start Date*: 2008-10-01 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A Multi-Centre, Double-Blind, Placebo-Controlled, Parallel-Group Induction-Design Study to assess the Clinical Effect of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxyl... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (Pharmacodynamic, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003054-16 | Sponsor Protocol Number: DDZ-BOND-2017 | Start Date*: 2018-07-27 | |||||||||||
Sponsor Name:Wörwag Pharma GmbH & co. KG | |||||||||||||
Full Title: Randomized double-blind, placebo-controlled parallel group study over 12 months to assess the effects of treatment with benfotiamine on morphometric, neurophysiological, and clinical measures in ty... | |||||||||||||
Medical condition: diabetic polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005701-22 | Sponsor Protocol Number: Droxidopa-303 | Start Date*: 2009-04-13 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A MULTI-CENTER, OPEN-LABEL STUDY, WITH A TWO WEEK RANDOMIZED, PLACEBO-CONTROLLED, WITHDRAWAL PERIOD, TO ASSESS THE LONG-TERM SAFETY AND CLINICAL BENEFIT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONO... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-004375-12 | Sponsor Protocol Number: TODINELI | Start Date*: 2014-02-13 | |||||||||||||||||||||
Sponsor Name:Center of Mech-Sense | |||||||||||||||||||||||
Full Title: TODINELI Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of the neuroprotective effect of Liraglutide for treatment of diabetic neuropathy | |||||||||||||||||||||||
Medical condition: TODINELI Trial A randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of the neuroprotective effect of Liraglutide for treatment of diabetic neuropathy i... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001066-16 | Sponsor Protocol Number: H23750 | Start Date*: 2007-01-04 |
Sponsor Name:John L. Berk, M.D. | ||
Full Title: The effect of diflunisal (IND 68092) on familial amyloidosis | ||
Medical condition: Familial Amyloid Polyneuropathy (FAP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005673-60 | Sponsor Protocol Number: Droxidopa-302 | Start Date*: 2009-04-22 |
Sponsor Name:Chelsea Therapeutics Inc | ||
Full Title: A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP WITHDRAWAL-DESIGN STUDY TO ASSESS THE CLINICAL EFFECT OF DROXIDOPA IN SUBJECTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE ... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), DBH deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003016-45 | Sponsor Protocol Number: APCP-112 | Start Date*: 2013-09-11 |
Sponsor Name:Araim Pharmaceuticals | ||
Full Title: A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis | ||
Medical condition: small fiber neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-007105-36 | Sponsor Protocol Number: Droxidopa-304 | Start Date*: 2009-06-03 |
Sponsor Name:Chelsea Therapeutics Inc. | ||
Full Title: A Multi-Centre, One Year Open-Label Study to Assess the Long-Term Safety of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and... | ||
Medical condition: Symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure (PD, MSA and PAF), Dopamine Beta Hydroxylase deficiency and Non-Diabetic Neuropathy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-003519-24 | Sponsor Protocol Number: ALN-TTR02-008 | Start Date*: 2019-03-12 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Disease Progressi... | ||||||||||||||||||
Medical condition: Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) FR (Completed) PT (Completed) DE (Completed) ES (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002320-25 | Sponsor Protocol Number: UC_0106/1712 | Start Date*: 2018-07-03 |
Sponsor Name:UNICANCER | ||
Full Title: Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS. | ||
Medical condition: Colorectal cancer stage II/III with adjuvant oxaliplatin-based chemotherapy (simplified FOLFOX4) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001511-70 | Sponsor Protocol Number: 44313 | Start Date*: 2015-08-05 |
Sponsor Name:Maastricht University Medical Center | ||
Full Title: Efficacy, safety and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutations related small fiber neuropathy: a randomized, double-blind, placebo controlled, crossover trial | ||
Medical condition: SCN9A mutation related small fiber neuropathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002940-22 | Sponsor Protocol Number: STARDUST | Start Date*: 2021-01-13 | |||||||||||
Sponsor Name:A.O.U. Università degli Studi della Campania "Luigi Vanvitelli" | |||||||||||||
Full Title: EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY DISEASE: A RANDOMIZED CONTROLLED TRIAL | |||||||||||||
Medical condition: Peripheral Artery Disease and type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002136-90 | Sponsor Protocol Number: JH/TJ1_NAT_2012 | Start Date*: 2012-06-19 |
Sponsor Name:Rigshospitalet | ||
Full Title: Treatment of hypertension at nigth in type 1 diabetes patients with no 24 hour variation of thier bloodpressure. | ||
Medical condition: Patients with type 1 diabetes with autonomic neuropathy or no 24h variation in bloodpressure. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001427-40 | Sponsor Protocol Number: ION-682884-CS13 | Start Date*: 2022-06-07 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | |||||||||||||
Medical condition: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) CY (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003287-18 | Sponsor Protocol Number: PET-FRAX-001 | Start Date*: 2008-09-17 |
Sponsor Name:University Antwerp [...] | ||
Full Title: Functional consequences of decreased RNA expression of certain GABA(A) receptor subunits in fragile X patients using Positron Emission Tomography and [11C]flumazenil. | ||
Medical condition: Fragile X syndrome is the most common form of inherited mental retardation with a prevalence of 1/4000 males and 1/6000 females. Patients are characterized by a mild to severe form of cognitive imp... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002987-17 | Sponsor Protocol Number: ALN-TTR02-004 | Start Date*: 2013-11-25 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc | ||||||||||||||||||
Full Title: APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneu... | ||||||||||||||||||
Medical condition: Transthyretin mediated amyloidosis (ATTR) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) ES (Completed) PT (Completed) IT (Completed) DE (Completed) NL (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002624-31 | Sponsor Protocol Number: NL53861.068.15 | Start Date*: 2015-12-23 |
Sponsor Name:Maastricht UMC | ||
Full Title: Intravenous immunoglobulin therapy for small fiber neuropathy: a randomised, double-blind, placebo-controlled study on efficacy and safety. | ||
Medical condition: Skin-biopsy proven small fiber neuropathy without an underlying cause | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004670-10 | Sponsor Protocol Number: AG10-333 | Start Date*: 2020-07-07 | |||||||||||
Sponsor Name:Eidos Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) | |||||||||||||
Medical condition: Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) FR (Completed) BG (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005590-32 | Sponsor Protocol Number: APCP-113 | Start Date*: 2013-02-20 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: A double blind, placebo controlled Phase 2 study comparing the effects of ARA 290 on neuropathic symptoms of patients with type 2 diabetes | ||
Medical condition: Diabetes type 2: neuropathic symptoms | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006791-12 | Sponsor Protocol Number: Fx1A-201 | Start Date*: 2008-04-02 |
Sponsor Name:FoldRx Pharmaceuticals Limited | ||
Full Title: The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients with Non-V30M Transthyretin Amyloidosis | ||
Medical condition: Non-V30M Transthyretin Amyloidosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) IT (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
